Hydrogen Nanotherapy Shows Promise Against Colorectal Cancer
- Authors
- Zhiyue Cao, Rui Xin, Qiuyue Ma, Qinghui Wang, Shuaiyang Feng, Huiyu Su, Ayang Zhao, Kai Li, Shujuan Liu, Liangcan He, Shaoqin Liu
- Journal
- ACS Nano
- Year
- 2025
- DOI
- 10.1021/acsnano.5c10754
- Study Type
- Cell Culture
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- China
- Health Condition
- Colorectal Cancer
- Body System
- Digestive System
TL;DR
A light-activated nanoparticle released hydrogen and 5-ASA to push colorectal tumors into dormancy and make them more vulnerable to oxidative destruction.
Key Finding
A platinum-based nanomaterial that generates hydrogen gas and releases 5-aminosalicylic acid suppressed colorectal cancer cells in laboratory cultures by inducing dormancy (cell cycle arrest) while simultaneously blocking tumor-protective signaling pathways.
Summary
Researchers created a tiny engineered material containing platinum that generates hydrogen gas when exposed to light and releases a drug called 5-aminosalicylic acid. In laboratory cell cultures of colorectal cancer, this combination worked through two mechanisms: the hydrogen gas put cancer cells into a dormant (inactive) state by disrupting their energy balance, while the drug blocked a protein called NF-κB that helps tumors survive. Together, these actions stopped cancer cells from dividing and made them vulnerable to damage.
Practical Takeaway
This is very early-stage laboratory research using engineered nanomaterials and cell cultures, not human studies or even animal testing. While it provides mechanistic evidence that hydrogen gas may contribute to cancer cell suppression, it is far too preliminary to draw any conclusions about hydrogen water's effects on human cancer. Significant development and clinical testing would be needed before any therapeutic application.
Abstract
Colorectal cancer remains a therapeutic challenge due to systemic toxicity and the suboptimal efficacy of conventional therapies. Emerging evidence indicates that molecular hydrogen (H2) exerts antitumor effects through proliferation suppression and induction of a "tumor dormancy" phenotype characterized by cell cycle arrest and metabolic quiescence. Capitalizing on this mechanism, we engineered a platinum-incorporated metal-organic framework (PM) that integrates H2-mediated dormancy induction with 5-aminosalicylic acid (5-ASA)-potentiated NF-κB suppression. This system enables spatiotemporally light-controlled H2 generation vis-à-vis water splitting, which disrupts redox homeostasis while synchronously releasing 5-ASA to block NF-κB nuclear translocation, thereby collectively inducing sustained proliferative arrest and immunosuppressive tumor microenvironment remodeling. Tumor-localized PM decomposition generates photosensitizers that amplify therapeutic efficacy through catalytic ROS storms, representing a dual-modality strategy that couples H2-driven dormancy with ROS-mediated cytotoxicity. Mechanistic profiling reveals NF-κB suppression via modulation of the H2/5-ASA-mediated redox-inflammatory axis, systematically validated through multiomics analyses across three tumor models and clinical specimens. H2-induced dormancy sensitizes tumors to catalytic ROS attacks by potentiating metabolic vulnerabilities, while 5-ASA prevents dormancy from escaping through persistent NF-κB inactivation. This work introduces a nanomaterial-enabled approach to dormancy therapy, demonstrating the dual functionality of single-atom catalysts in precision catalytic H2 generation and immunomodulatory integration. It proposes a framework for intercepting tumor progression via coordinated cell cycle control and microenvironmental reprogramming.